Dr. Hasenin Raid Hashim Al-Khersan, MD

Dr. Al-Khersan practices at Retina Consultants of Houston in Bellaire, Texas.

Dr. Al-Khersan's NPI, 1245761972, was assigned on March 24, 2017. Dr. Al-Khersan graduated from Pritzker School of Medicine in 2017. Dr. Al-Khersan's Florida license number on file is ME149383.

Dr. Al-Khersan's primary practice is Retina Consultants of Houston, at 6300 W S Loop, Bellaire, TX 77401 in Harris County. The practice phone is (713) 524-3434.

Dr. Al-Khersan's primary practice is Retina Consultants of Houston in Bellaire, Texas. Dmand AI also links Dr. Al-Khersan to 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Al-Khersan practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Al-Khersan's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Al-Khersan is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Al-Khersan's licenses on file in 3 states: Florida, Texas and Illinois.

Dmand AI lists age-related macular degeneration, cataract surgery with lens implant, glaucoma, retinal detachment, surgical retina and vitreous procedures and vitreous eye degeneration among the conditions Dr. Al-Khersan treats.

CMS data shows 10,558 Medicare services from Dr. Al-Khersan across 17 procedure codes in 2024, for 659 Medicare patients. Medicare paid $1,511,489 for them. Every service was in an office.

CMS counts 659 Medicare patients who saw Dr. Al-Khersan in 2024. The largest group is 65 to 74, with 297 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Al-Khersan's median patient age at 68, with 52% women.

In 2024, Dr. Al-Khersan wrote 282 Medicare Part D claims for 120 patients. 63% of them were for generic drugs. CMS names the drug for 238 of them, across 7 drugs with 11 or more claims each, at $7,536 in total drug cost. In 2023, CMS named 448 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Al-Khersan for performance year 2024, reported as part of a group. Dr. Al-Khersan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 79 papers to Dr. Al-Khersan, published from 2017 to 2025. 2020 was the busiest year, with 14. The most frequent topics are Visual Acuity, Retinopathy of Prematurity and Tomography, Optical Coherence. Dr. Al-Khersan has published most often in Ophthalmol Retina. Dr. Al-Khersan's most frequent co-authors are Kenneth Chen Fan, MBA, MD, Nicolas A. Yannuzzi, MD and Jayanth Srinivasan-Kasi Sridhar, MD.

CMS Open Payments shows 183 general payments to Dr. Al-Khersan from 21 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 66% of the total. Apellis Pharmaceuticals, Inc. paid the most, $18,545. It also lists 1 research payment totaling $9,600 in 2025.

Dr. Al-Khersan graduated from Pritzker School of Medicine in 2017. Dr. Al-Khersan is a member of ARVO.

Dr. Al-Khersan is in network with 22 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.